Website Video

Partner of choice in specialty, hospital, and rare disease medicines

Learn More

ADVANZ PHARMA is a global pharmaceutical company with the purpose to improve patients’ lives by providing the specialty, hospital, and rare disease medicines they depend on.

Our ambition is to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with innovative biopharma and pharmaceutical development companies to bring medicines to patients.

Headquartered in London, UK, we have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia.

Our Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialisation partner network complement our global operations.

ADVANZ PHARMA’s product portfolio and pipeline comprises innovative medicines, specialty generics & biosimilars, and originator brands. Our products and pipeline cover a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, CNS, and, more broadly, rare diseases.

We can only achieve our ambition with the passion of our dedicated and highly qualified people, acting in line with our company values of entrepreneurship, speed, and integrity.

Latest News —

Image for ADVANZ PHARMA secures temporary suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe

Press Releases — 05 Sep 2024

ADVANZ PHARMA secures temporary suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe

Learn more
Image for ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC)

Press Releases — 03 Sep 2024

ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC)

Learn more
Image for ADVANZ PHARMA and Enzene Enter an Exclusive Partnership for Biosimilar Development and Commercialisation

Press Releases — 27 Aug 2024

ADVANZ PHARMA and Enzene Enter an Exclusive Partnership for Biosimilar Development and Commercialisation

Learn more
Image for European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Press Releases — 15 Aug 2024

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Learn more
Image for ADVANZ PHARMA response to CHMP recommendation pertaining to EU conditional marketing authorization for OCALIVA® in rare disease Primary Biliary Cholangitis

Press Releases — 01 Jul 2024

ADVANZ PHARMA response to CHMP recommendation pertaining to EU conditional marketing authorization for OCALIVA® in rare disease Primary Biliary Cholangitis

Learn more
Image for Alvotech and ADVANZ PHARMA Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe

Press Releases — 18 Jun 2024

Alvotech and ADVANZ PHARMA Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe

Learn more

Our portfolio —

ADVANZ PHARMA’s product portfolio and pipeline comprises innovative medicines, specialty generics & biosimilars, and originator brands

Our products cover a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare diseases.

Careers & Culture —

The success of any company is driven by its people, and we are no different. We aim to be the best team in the industry by embracing challenges and change. We live our company values Entrepreneurship, Speed, and Integrity.

Our Partnerships —

Partnerships are a fundamental part of our business.. We work with >300 partners in production, development, portfolio licensing, and commercialization. We cooperate very closely with them and invest significantly to help broaden patient access and to improve health outcomes.

Subscribe for the latest press releases delivered to your inbox

Please select all the ways you would like to hear from ADVANZ PHARMA:

You can unsubscribe at any time by clicking the link in the footer of our emails.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.